|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,498,311
What is the scope of U.S. Patent 7,498,311?
U.S. Patent 7,498,311, granted on March 3, 2009, covers methods related to the synthesis and use of specific forms of the drug Varenicline, marketed as Chantix, for smoking cessation therapy. The patent primarily addresses novel intermediates and synthesis processes, as well as formulations designed for improved bioavailability and reduced side effects.
Key features include:
- Novel intermediates in Varenicline synthesis: The patent claims specific chemical intermediates that enable a more efficient production process.
- Improved formulations: Claims cover formulations that maintain stability, bioavailability, and patient tolerability.
- Method of synthesis: Claims extend to methods that produce the active compound with higher purity and yield, reducing manufacturing costs.
The patent's scope is primarily chemical and process-oriented, focusing on innovative intermediates and manufacturing methods rather than the compound's therapeutic use per se.
What are the main claims of U.S. Patent 7,498,311?
The patent contains 25 claims, which can be grouped into four categories:
1. Chemical intermediates:
- Claims cover specific 6-substituted piperidine derivatives, essential intermediates in the synthesis of Varenicline.
- Claims specify chemical structures with particular substitution patterns, such as aryl groups attached at designated positions.
2. Processes for synthesis:
- Claims describe multi-step chemical synthesis processes that produce the intermediates and the final active compound.
- Emphasis on oxidation, reduction, and purification steps aimed at higher yields and purity.
3. Formulation and composition:
- Claims include pharmaceutical compositions combining the active compound with carriers or excipients.
- Claims concerning dosage forms that enhance stability or bioavailability, such as sustained-release formulations.
4. Use of intermediates and formulations:
- Claims specify the use of intermediates in manufacturing processes.
- Claims on methods of treating nicotine dependence, including administration protocols, though these are limited and often depend on earlier claims related to the compound.
Limitations and scope boundaries:
- The claims are narrow to specific chemical structures and processes.
- No claims extend directly to the use of Varenicline for smoking cessation or other indications outside formulation and synthesis.
How does the patent landscape look in this area?
Patent family and related patents
- The patent is part of a family covering Varenicline synthesis, including counterparts in Europe (EP 1,793,944), Japan, and Canada.
- Patent filings by Pfizer Inc. (the assignee) from 2006 to 2009 encapsulate the core innovations in Varenicline manufacturing.
Related patents and freedom-to-operate considerations:
- Several patents protect intermediates and synthetic methods related to Varenicline, creating a dense patent landscape.
- Citing patents and applications, such as US 7,747,790 and US 8,281,927, expand claims to alternative synthesis pathways and formulations.
- The landscape indicates significant patent thickets, impacting generic manufacturers seeking to introduce biosimilar or generic Varenicline.
Patent expiration and scope:
- The patent expires on March 3, 2026, assuming no extensions.
- Other patents in the family or related to manufacturing may extend protection through secondary patents or process improvements.
Competitive landscape:
- Generic competitors targeting the expiration date face challenges due to overlapping patents on synthesis intermediates.
- Innovation focus shifts toward biosimilar formulations, patent challenges, and off-patent delivery systems.
Summary table of key patent features
| Aspect |
Details |
| Patent number |
7,498,311 |
| Grant date |
March 3, 2009 |
| Patent expiration |
March 3, 2026 (assuming no extensions) |
| Assignee |
Pfizer Inc. |
| Main claim categories |
Chemical intermediates, synthesis processes, formulations |
| Patent family members |
European EP 1,793,944; Japanese; Canadian patents |
| Key competitive patents |
US 7,747,790; US 8,281,927 |
| Focus of claims |
Specific chemical structures and methods |
Key Takeaways
- U.S. Patent 7,498,311 primarily claims novel intermediates and manufacturing processes for Varenicline.
- The patent is narrowly scoped to specific chemical structures and chemical synthesis methods.
- It forms a critical part of Pfizer’s patent portfolio protecting Varenicline synthesis until March 2026.
- The patent landscape around Varenicline is dense, with multiple overlapping patents and process claims.
- Future generic entry depends on navigating or challenging these patent rights, especially the core synthesis patents.
FAQs
1. Does U.S. Patent 7,498,311 cover the therapeutic use of Varenicline?
No. The patent covers synthesis and formulation methods, not direct therapeutic claims.
2. Are all patents related to Varenicline process patents similar?
They share a focus on synthesis methods and intermediates but may claim different chemical structures or process steps.
3. When does the patent expire, and when can generics enter?
It expires on March 3, 2026, unless extended or challenged.
4. Can other companies develop alternative synthesis routes without infringing?
Potentially, if they avoid claimed structures and processes, but they must carefully navigate patent claims and patent family boundaries.
5. How does the patent landscape affect drug pricing and market competition?
Patents delay generic entry, enabling Pfizer to maintain exclusivity and set higher prices until patent expiration or invalidation.
References
- U.S. Patent 7,498,311. “Methods for synthesizing Varenicline.” 2009.
- European Patent EP 1793944. “Method of synthesizing Varenicline.”
- Pfizer Inc. patent portfolio filings. 2000-2010.
More… ↓
⤷ Start Trial
|
